Fennec Pharmaceuticals Inc.
- FENC
- NASDAQ
- Biotechnology
- Biopharma (Ototoxicity Prevention)
- Cancer Support Therapy
$10.27
Today +2.91%Quote Oct 19, 2026, 08:00 PM UTC
−3.30%over the last month
Max drawdown −9.4%From 1-month high −6.7%3 months −1.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate.
Where the money comes from
Q2 2026 revenue $19.6M
- Manufactured Product, Other$18.9M96.4%
- Service, Other$710,0003.6%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
35
Founded
1996
Market value
$360.1M
Quote Oct 19
Analyst target
$16.00
+55.8% from here
Floor
$10.23
0.4% below price
Resistance
$10.31
0.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FENCPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free